These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31995663)

  • 1. Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
    Pan S; Tsakok T; Dand N; Lonsdale DO; Loeff FC; Bloem K; de Vries A; Baudry D; Duckworth M; Mahil S; Pushpa-Rajah A; Russell A; Alsharqi A; Becher G; Murphy R; Wahie S; Wright A; Griffiths CEM; Reynolds NJ; Barker J; Warren RB; David Burden A; Rispens T; Standing JF; Smith CH;
    Clin Transl Sci; 2020 Mar; 13(2):400-409. PubMed ID: 31995663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
    Salinger DH; Endres CJ; Martin DA; Gibbs MA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).
    Blauvelt A; Ferris LK; Yamauchi PS; Qureshi A; Leonardi CL; Farahi K; Fakharzadeh S; Hsu MC; Li S; Chevrier M; Smith K; Goyal K; Chen Y; Muñoz-Elías EJ; Callis Duffin K
    Br J Dermatol; 2017 Dec; 177(6):1552-1561. PubMed ID: 28600818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
    Landells I; Marano C; Hsu MC; Li S; Zhu Y; Eichenfield LF; Hoeger PH; Menter A; Paller AS; Taieb A; Philipp S; Szapary P; Randazzo B
    J Am Acad Dermatol; 2015 Oct; 73(4):594-603. PubMed ID: 26259989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    López Jiménez P; Suárez Pérez J; Herrera Acosta E; Aguilera Arjona J; Mendiola Fernández MV; Bosch García R; Herrera Ceballos E
    Dermatol Ther; 2019 Jul; 32(4):e12937. PubMed ID: 30983098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
    Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.
    Romero-Jimenez RM; Escudero-Vilaplana V; Baniandres Rodriguez O; García Martín E; Mateos Mayo A; Sanjurjo Saez M
    J Dermatolog Treat; 2018 Dec; 29(8):792-796. PubMed ID: 29676189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.
    Toro-Montecinos M; Ballescá F; Ferrandiz C; Teniente-Serra A; Martinez-Caceres E; Carrascosa JM
    J Dermatolog Treat; 2019 Feb; 30(1):35-39. PubMed ID: 29683393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.
    Wcisło-Dziadecka D; Grabarek B; Kruszniewska-Rajs C; Strzałka-Mrozik B
    Dermatol Ther; 2019 May; 32(3):e12843. PubMed ID: 30693647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
    Langley RG; Lebwohl M; Krueger GG; Szapary PO; Wasfi Y; Chan D; Hsu MC; You Y; Poulin Y; Korman N; Prinz JC; Reich K;
    Br J Dermatol; 2015; 172(5):1371-83. PubMed ID: 25307931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
    Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
    Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
    van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
    Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab.
    Weber J; Keam SJ
    BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.
    Menting SP; van den Reek JM; Baerveldt EM; de Jong EM; Prens EP; Lecluse LL; Wolbink GJ; Van der Kleij D; Spuls PI; Rispens T
    Br J Dermatol; 2015 Sep; 173(3):855-7. PubMed ID: 25865153
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
    Zhou W; Hu C; Zhu Y; Randazzo B; Song M; Sharma A; Xu Z; Zhou H
    Clin Pharmacol Ther; 2021 Jan; 109(1):131-139. PubMed ID: 32865226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.